Celgene beats Street

Celgene Corp. (NASDAQ:CELG) reported 3Q09 non-GAAP diluted EPS of $0.56, beating by $0.02 the Street's estimate of $0.54 and up 40% from $0.40 in 3Q08. Third quarter non-GAAP revenues rose 18% to $692.2 million. Sales of Revlimid lenalidomide for multiple myeloma (MM) and myelodysplastic syndromes (MDS) rose 31% to $449.6 million in the quarter. ...